Alvotech (ICE:ALVO)
1,125.00
0.00 (0.00%)
At close: Jun 25, 2025
Alvotech Revenue
Alvotech had revenue of $132.81M USD in the quarter ending March 31, 2025, with 259.97% growth. This brings the company's revenue in the last twelve months to $587.89M, up 413.92% year-over-year. In the year 2024, Alvotech had annual revenue of $491.98M with 426.84% growth.
Revenue (ttm)
$587.89M
Revenue Growth
+413.92%
P/S Ratio
4.38
Revenue / Employee
$580.92K
Employees
1,012
Market Cap
340.09B ISK
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Marel | 250.20B |
Íslandsbanki | 62.96B |
Arion banki | 61.68B |
Sildarvinnslan Hf. | 43.52B |
Brim hf. | 58.07B |
Hagar | 177.12B |
Kvika banki | 15.14B |
Festi | 147.75B |
Alvotech News
- 2 days ago - Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility - GlobeNewsWire
- 3 days ago - Main Results of 2025 Annual and Extraordinary General Meeting - GlobeNewsWire
- 3 days ago - Main Results of 2025 Annual and Extraordinary General Meeting - GlobeNewsWire
- 3 days ago - Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewsWire
- 3 days ago - Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewsWire
- 5 days ago - European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept) - GlobeNewsWire
- 5 days ago - European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept) - GlobeNewsWire
- 17 days ago - Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors - GlobeNewsWire